Skip to main content

Day: May 25, 2023

Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingTo access the press release, please click here.

Continue reading

SCOR’s Combined General Meeting of 25 May 2023: SCOR shareholders adopt all the proposed resolutions

Press Release25 May 2023 – N° 10 SCOR’s Combined General Meeting of 25 May 2023 SCOR shareholders adopt all the proposed resolutions, as the Group outlines its new strategic plan and further strengthens its sustainable underwriting commitments The Combined General Meeting of SCOR SE was held on 25 May 2023, at the Group’s headquarters at 5, avenue Kléber, 75016 Paris, and was chaired by Denis Kessler, Chairman of the Board of Directors of SCOR SE. All the resolutions proposed by the Board of Directors were approved by the General Meeting. The General Meeting approved the appointment of SCOR SE CEO Thierry Léger as a director of SCOR SE. The General Meeting ratified the provisional appointment of Martine Gerow as a director. It also approved the renewal of the director mandates of Augustin de Romanet, Adrien Couret, Martine Gerow,...

Continue reading

Mithra’s General Meeting Of Shareholders Approves the Renewal of its Board of Directors

Liege, Belgium, 25 MAY 2023 – 5:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that at its Annual General Meeting, held today all agenda items put to vote were approved, including the appointment of Directors for a two-year mandate. The Board of Directors is now made up of 7 members with varied backgrounds spanning both the financial and pharmaceutical sectors, bringing extensive expertise to Mithra covering all aspects of pharmaceutical development. The Board will include four new Directors, including: Ribono SRL, Mr. Sidney Bens (Independent Director) Sidney is a seasoned financial executive, with over 35 years’ experience. He spent most of his career at Atenor, an international real estate development company listed on Euronext,  where he served as Chief Financial Officer. Prior...

Continue reading

Press Release – Half-Yearly Financial Report

Half-yearly financial report of Ascencio SA – Results to 31 March 2023                                EPRA RESULTS UP & STRONG PERFORMANCE OF THE REAL ESTATE PORTFOLIO OPERATING RESULTS – RENTAL INCOME:  €25.1 million, up by 6.1% compared with the €23.6 million at 31/03/2022 – EPRA OCCUPANCY RATE: 97.2%, up from the 96.5% at 30/09/2022 – EPRA RESULTS: €17.5 million, up by 7.8% compared with €16.2 million at 31/03/2022 – EPRA RESULTS PER SHARE: €2.65 as against €2.46 at 31/03/2022 – NET RESULT: €22.2 million compared with €44.0 million at 31/03/2022, the decrease being due to the difference in positive revaluations compared to 31/03/2022 (+€5.0 million against +€28.2 million) BALANCE SHEET INFORMATION – FAIR VALUE OF THE PORTFOLIO: €748.6 million compared with €738.9 million at 30/09/2022 –...

Continue reading

Coface records a very good start to the year with a net income of €61.2m

Coface records a very good start to the year with a net income of €61.2m Paris, 25 May 2023 – 17.35Coface applied IFRS 17 and IFRS 9 accounting standards starting on 1 January 2023. All comparisons are made using the 2022 pro forma IFRS 17 figures presented on 27 April 2023 Turnover: €475m, up 11.4% at constant perimeter and FXTrade Credit insurance rose 10.9% at constant FX, driven by increased client activity and growth in fee and commission income (+12.8%) Client retention stood at record highs (95.7%); the price effect was still negative (-1.5%) but less so than Q4-22 Information services rose 15.0% at constant FX, while factoring climbed 13.1%Net loss ratio at 40.6%, up by 0.3 ppt; net combined ratio at 66.3%, improved by 1.7 ppt (+10.3 ppts compared to Q1-22, excluding the impact of government schemes)Gross loss ratio at...

Continue reading

Form 8.3 – CT Property Trust Ltd

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CT Property Trust PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

Correction: Form 8.3 – LondonMetric Property PLC

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LondonMetric Property PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening...

Continue reading

CGrowth Capital Consolidates Lithium Tenement Portfolio in Tanzania Amid Renewed Mining Confidence

NEW YORK, NY, May 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and is solely focused on investing in growth-oriented opportunities where the company’s capital, expertise, and capabilities can help create significant added value for shareholders. CGrowth Capital Inc. is pleased to offer an update following its acquisition of a series of lithium tenements in the Hombolo region of Tanzania. The company has successfully consolidated 17 prospecting licenses and 37 primary licenses, encompassing a 435 square kilometer area, following negotiations with 54 individual mining owners. “This acquisition was no small feat and is the culmination of 12 months’ worth of hard work behind the scenes...

Continue reading

Puma Exploration Focused on Building a Gold Camp at its Williams Brook Gold Project

Figure 1: Main gold showings and occurrences at the Williams Brook Gold Project Main gold showings and occurrences at the Williams Brook Gold ProjectFigure 2: Williams Brook Gold Project in Northern New Brunswick Williams Brook Gold Project in Northern New BrunswickFigure 3: Gold enrichment drilling targets at the Lynx Gold Zone Gold enrichment drilling targets at the Lynx Gold ZoneFigure 4: Lynx Gold Zone 3km lateral extension towards NE Lynx Gold Zone 3km lateral extension towards NEFigure 5: The trenching operation currently in progress at the Williams Brook property The trenching operation currently in progress at the Williams Brook propertyRIMOUSKI, Quebec, May 25, 2023 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to announce its 2023 exploration strategy...

Continue reading

Nox Health Acquires Somryst, the Only FDA-Cleared Digital Insomnia Treatment

Sleep Health Leader Further Elevates Behavioral Sleep Care Management ProgramNox Health & Somryst Nox Health acquires SomrystALPHARETTA, Ga. , May 25, 2023 (GLOBE NEWSWIRE) —  Nox Health, a global sleep health leader, has acquired Somryst, the first FDA-cleared Prescription Digital Therapeutic (PDT) that delivers effective, first-line treatment for adults with chronic insomnia. This acquisition deepens the Nox value-based healthcare programs, as it seeks to reframe sleep as a critical and powerful intervention strategy for chronic health conditions management. “The acquisition of Somryst aligns seamlessly with Nox’s mission of promoting science-based solutions that address chronic diseases through sleep care management. As an outcomes-driven company with ten years of real-world data, it was important for us to find...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.